CCL2 has a strong link to chemotherapy and radiotherapy resistance and tumor progression in breast 39, 40, 57, prostate 38, 58-60, pancreatic 61, melanoma 62, lung 63, renal 64 and ovarian 65 cancers. Here, CCL2 is linked to neoplasm.